| Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX (NCT00590213) | AstraZeneca | 2003-06-01 |
| Factorial Study of Metoprolol Succinate TOPROL-XL (324A) (NCT00642096) | AstraZeneca | 2003-06-01 |
| Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin (NCT00082381) | AstraZeneca | 2003-06-01 |
| Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer (NCT00239304) | AstraZeneca | 2003-06-01 |
| Study of Multiple Doses of Saxagliptin (BMS-477118) (NCT00950599) | AstraZeneca | 2003-05-01 |
| Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP) (NCT00653965) | AstraZeneca | 2003-05-01 |
| Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke (NCT00061022) | AstraZeneca | 2003-05-01 |
| Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCT (NCT00246974) | AstraZeneca | 2003-05-01 |
| Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS) (NCT00660764) | AstraZeneca | 2003-05-01 |
| Symbicort Onset of Action 1 (NCT00646620) | AstraZeneca | 2003-04-01 |
| Efficacy of Symbicort pMDI Administered Once Daily in Children and Adolescents During 12 Weeks - SPROUT (NCT00646321) | AstraZeneca | 2003-04-01 |
| Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus (NCT00108004) | AstraZeneca | 2003-04-01 |
| Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM (NCT00652392) | AstraZeneca | 2003-04-01 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD) (NCT00628342) | AstraZeneca | 2003-04-01 |
| Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205) (NCT00163410) | AstraZeneca | 2003-04-01 |
| Adults With Moderate to Severe Asthma (NCT00642122) | AstraZeneca | 2003-04-01 |
| Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013) (NCT00163527) | AstraZeneca | 2003-04-01 |
| High Doses of Candesartan Cilexetil on the Reduction of Proteinuria (NCT00242346) | AstraZeneca | 2003-04-01 |
| Rhinocort Aqua Versus Placebo and Fluticasone Propionate (NCT00641680) | AstraZeneca | 2003-04-01 |
| Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks (NCT00653588) | AstraZeneca | 2003-04-01 |
| A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD) (NCT00626535) | AstraZeneca | 2003-03-01 |
| Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129) (NCT00163332) | AstraZeneca | 2003-03-01 |
| Symbicort Onset of Action 2 (NCT00646009) | AstraZeneca | 2003-03-01 |
| Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia (NCT00240357) | AstraZeneca | 2003-02-01 |
| Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases (NCT00501605) | AstraZeneca | 2003-02-01 |
| Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET) (NCT00396110) | AstraZeneca | 2003-02-01 |
| Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines (NCT00240292) | AstraZeneca | 2003-02-01 |
| A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme (NCT00238797) | AstraZeneca | 2003-02-01 |
| JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events (NCT00239681) | AstraZeneca | 2003-02-01 |
| Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. Ratio-Study. (BY217/M2-112) (NCT00430729) | AstraZeneca | 2003-01-01 |
| Trial of Iressa in Prostate Cancer Patients (NCT00265070) | AstraZeneca | 2003-01-01 |
| AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD) (NCT00240331) | AstraZeneca | 2003-01-01 |
| PPI Test in GP Patients (NCT00318084) | AstraZeneca | 2003-01-01 |
| The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study (NCT00240279) | AstraZeneca | 2003-01-01 |
| Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer (NCT00239291) | AstraZeneca | 2003-01-01 |
| A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis (NCT00641602) | AstraZeneca | 2002-12-01 |
| Nexium Dyspepsia/AST (NCT00251914) | AstraZeneca | 2002-12-01 |
| Nexium Dyspepsia/AST (NCT00251992) | AstraZeneca | 2002-12-01 |
| IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (NCT00242749) | AstraZeneca | 2002-12-01 |
| Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma. (NCT00334295) | AstraZeneca | 2002-12-01 |
| Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed (NCT00644735) | AstraZeneca | 2002-12-01 |
| Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus (NCT00107107) | AstraZeneca | 2002-11-01 |
| New Version Pulmicort Turbuhaler USA Children (NCT00642161) | AstraZeneca | 2002-11-01 |
| Casodex - Nolvadex Combination (NCT00637871) | AstraZeneca | 2002-11-01 |
| Effects of Rosuvastatin on Aortic Stenosis Progression (NCT00800800) | AstraZeneca | 2002-11-01 |
| A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) (NCT00240318) | AstraZeneca | 2002-11-01 |
| Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes (NCT00111540) | AstraZeneca | 2002-11-01 |
| Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children (NCT00641472) | AstraZeneca | 2002-10-01 |
| Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS) (NCT00654225) | AstraZeneca | 2002-10-01 |
| Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler (NCT00658255) | AstraZeneca | 2002-10-01 |
| Adult Asthmatics and Acid Reflux (NCT00628953) | AstraZeneca | 2002-10-01 |
| Efficacy and Tolerability of Zolmitriptan Nasal Spray (NCT00617747) | AstraZeneca | 2002-09-01 |
| Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression (NCT00060489) | AstraZeneca | 2002-09-01 |
| Seroquel- Agitation Associated With Dementia (NCT00621647) | AstraZeneca | 2002-09-01 |
| Extension Study for 2993-112 (NCT01789957) | AstraZeneca | 2002-09-01 |
| ZD1839 (Iressa™) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer (NCT00247481) | AstraZeneca | 2002-09-01 |
| An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) (NCT00629564) | AstraZeneca | 2002-09-01 |
| IIIb 6 Week Open Label Multicentre Rosuvastatin & Simvastatin (NCT00654446) | AstraZeneca | 2002-09-01 |
| Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) (NCT00625495) | AstraZeneca | 2002-09-01 |
| Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5 (NCT00651651) | AstraZeneca | 2002-08-01 |
| Arimidex in McCune Albright Syndrome (NCT00055302) | AstraZeneca | 2002-08-01 |
| IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer (NCT00234416) | AstraZeneca | 2002-08-01 |
| A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR) (NCT00225589) | AstraZeneca | 2002-08-01 |
| A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer (NCT00590278) | AstraZeneca | 2002-08-01 |
| Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus (NCT00044694) | AstraZeneca | 2002-08-01 |
| Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously (NCT00635414) | AstraZeneca | 2002-08-01 |
| Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide (NCT00044707) | AstraZeneca | 2002-08-01 |
| Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination (NCT00044668) | AstraZeneca | 2002-08-01 |
| Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5 (NCT00652002) | AstraZeneca | 2002-07-01 |
| Symbicort in Asthmatic Children - SEEDLING (NCT00651547) | AstraZeneca | 2002-07-01 |
| 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects (NCT00255502) | AstraZeneca | 2002-07-01 |
| ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer (NCT00252798) | AstraZeneca | 2002-07-01 |
| Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects (NCT00255528) | AstraZeneca | 2002-07-01 |
| Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv (NCT00626262) | AstraZeneca | 2002-07-01 |
| Evaluation of the Effect of Pramlintide on Satiety and Food Intake (NCT00042601) | AstraZeneca | 2002-07-01 |
| Long-Term Safety of Symbicort in Asthmatic Children - SAPLING (NCT00646529) | AstraZeneca | 2002-07-01 |
| New Version Pulmicort Turbuhaler USA Adults (NCT00642187) | AstraZeneca | 2002-07-01 |
| Evaluation of the Bioavailability of Pramlintide (NCT00042471) | AstraZeneca | 2002-06-01 |
| Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR) (NCT00654173) | AstraZeneca | 2002-06-01 |
| Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD) (NCT00637845) | AstraZeneca | 2002-06-01 |
| Safety and Efficacy of Seroquel in First Episode Schizophrenia (NCT00254241) | AstraZeneca | 2002-05-01 |
| COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects (NCT00654485) | AstraZeneca | 2002-05-01 |
| Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus (NCT00035984) | AstraZeneca | 2002-05-01 |
| Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (NCT00254735) | AstraZeneca | 2002-04-01 |
| New Nasal Applicator / New Formulation - User Study (NCT00641979) | AstraZeneca | 2002-04-01 |
| GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes (NCT00280865) | AstraZeneca | 2002-04-01 |
| Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125) (NCT00546520) | AstraZeneca | 2002-04-01 |
| Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control (NCT00042458) | AstraZeneca | 2002-04-01 |
| Barrett's Esophagus - 315 - 3 Way Cross Over (NCT00637988) | AstraZeneca | 2002-04-01 |
| Barrett's Esophagus - 315 - 3 Way Cross-Over (NCT00637559) | AstraZeneca | 2002-03-01 |
| Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin (NCT00039013) | AstraZeneca | 2002-03-01 |
| CAFE Comparison of Atypicals in First Episode of Psychosis (NCT00034892) | AstraZeneca | 2002-03-01 |
| Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES) (NCT00653744) | AstraZeneca | 2002-03-01 |
| 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety (NCT00654602) | AstraZeneca | 2002-02-01 |
| Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux (NCT00628667) | AstraZeneca | 2002-02-01 |
| Rosuvastatin ORBITAL Germany (NCT00379249) | AstraZeneca | 2002-02-01 |
| ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals (NCT00396240) | AstraZeneca | 2002-02-01 |
| Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea (NCT00039026) | AstraZeneca | 2002-02-01 |
| Efficacy and Safety of Quetiapine Compared With Valproate in the Treatment of Patients With Bipolar Disorder and Rapid Cycling (NCT00254774) | AstraZeneca | 2002-01-01 |
| Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex (NCT00235937) | AstraZeneca | 2001-12-01 |